ASH: Patient Factors Affect Outcomes Among Older AML Patients Treated with Decitabine

Share this content:

ATLANTA — Patient age, baseline bone marrow blasts, platelet and WBC counts, and geography all modulate overall survival (OS)  benefits associated with decitabine for patients diagnosed with acute myeloid leukemia (AML) at age ≥65 years, according to analysis of data from a multinational Phase 3 trial presented during the 54th American Society of Hematology (ASH) Annual Meeting and Exposition.

“Treatment response is related to both patient and disease status in older patients with AML,” reported lead author Professor Jiří  Mayer, MD, PhD, of the Department of Internal Medicine, Hemato-Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic. In older patients with AML, overall survival was associated with the prognostic factors of age, ECOG PS (Eastern Cooperative Oncology Group Performance Status), cytogenetic risk, baseline bone marrow blasts, baseline platelet counts, and baseline WBC in addition to responding differently to decitabine versus patient treatment choice, supportive care, or cytarabine.

The phase 3 trial compared decitabine and supportive care or low-dose cytarabine (TC) in newly diagnosed de novo or secondary AML among older adults (age ≥65 years), with poor- or intermediate-risk cytogenetics. Of 485 study participants, 242 were randomized to receive decitabine and 243 to receive TC (cytarabine n=215; supportive care n=28), the authors reported.

“Patient characteristics that appeared to adversely affect OS at the 0.05 level included more advanced age, poorer baseline ECOG status, poor cytogenetics, higher bone marrow blast count, low baseline platelet count, high WBC count, and geographic region (Western vs Eastern Europe),” Dr. Mayer explained.

OS hazard ratios (HRs) were for decitabine vs TC, 0.80 (95% CI, 0.65-0.98; P=0.03); age 70-74 years vs <70 years (HR 1.31; 95% CI, 1.0-1.71; P=0.047); age ≥75 years vs < 70 years (HR 1.56; 95% CI, 1.20-2.03; P=0.001); intermediate vs poor baseline cytogenetic risk (HR 0.70; 95% CI, 0.57-0.87; P=0.001); baseline ECOG PS 0/1 vs 2 (HR 0.77; 95% CI, 0.61-0.98; P=0.032); Eastern vs Western Europe (HR 0.65; 95% CI, 0.48-0.88; P=0.005); baseline bone marrow blast >50% vs ≤50% (HR 1.36; 95% CI, 1.10-1.67; P=0.005); baseline platelets (109/L; [HR 0.78; 95% CI, 0.66-0.91; P=0.002]); and baseline WBC (109/L; [HR 1.26; 95% CI, 1.05-1.51; P=0.015]).

“Subgroup analyses suggest a greater response to decitabine vs cytarabine or standard care in patients aged ≥75 years, a population that is traditionally difficult to treat, with a poor prognosis,” noted Dr. Mayer.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs